Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Revenue (2016 - 2025)

Traws Pharma (TRAW) has disclosed Revenue for 14 consecutive years, with $2.7 million as the latest value for Q2 2025.

  • On a quarterly basis, Revenue rose 4694.74% to $2.7 million in Q2 2025 year-over-year; TTM through Sep 2025 was $2.8 million, a 1159.29% increase, with the full-year FY2024 number at $226000.0, changed 0.0% from a year prior.
  • Revenue was $2.7 million for Q2 2025 at Traws Pharma, up from $57000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.7 million in Q2 2025 to a low of $56000.0 in Q1 2021.
  • A 5-year average of $205222.2 and a median of $57000.0 in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: dropped 13.64% in 2021, then surged 4694.74% in 2025.
  • Traws Pharma's Revenue stood at $56000.0 in 2021, then changed by 0.0% to $56000.0 in 2022, then changed by 0.0% to $56000.0 in 2023, then changed by 0.0% to $56000.0 in 2024, then soared by 4780.36% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Revenue are $2.7 million (Q2 2025), $57000.0 (Q1 2025), and $56000.0 (Q4 2024).